Dementia treatments jump forward with government-backed funding
Seven Australian startups gain funding from the CUREator+ program. They will make therapies, diagnostics and digital tools for dementia and Parkinson's.
Melbourne's Kinoxis Therapeutics received $2.5 million for a treatment targeting long-term agitation and aggression in dementia. Tasmania's TasTest got the same amount for a digital tool that spots dementia risk decades before symptoms appear.
Victoria's Synerva Therapeutics secured $2.49 million to prevent nerve cell death in Parkinson's disease. Queensland's Quinthera received $2.43 million for an oral treatment that reduces brain swelling linked to Alzheimer's.
Western Australia's CodeBreakers was awarded $2.13 million for a gene editing treatment that targets childhood dementia caused by mitochondrial disease. Victoria's Healthily got $1.93 million to build an AI voice platform that spots cognitive decline earlier.
Queensland's Intracellica Bio secured $1.61 million for an antibody targeting tau in Alzheimer's.
- 7 startups
- Funding rounds
- 2.5 million dollars
- Largest grant
- 1.61 million dollars
- Smallest grant
- Dr Amanda Vrselja
- Program leader
Why it mattersThese therapies could slow, prevent or treat dementia and Parkinson's decades earlier than today's treatments allow.
AustraliaAustralian startups are leading research into early detection and new treatments. If successful, these tools and medicines could help hundreds of thousands of Australians and their families.
✓ Claims checked against the source and corrected before publish. checked 1 d ago
